🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

John M. Adams

The University of Texas at San Antonio Health Science Center

ORCID: 0000-0002-6794-6904

Also affiliated with Royal Berkshire Hospital, University Health System, Texas Diabetes Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion”.

Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion

Diabetes Care(2020)10.2337/dc19-2177
N/A
0.943DataRank · unranked
29 citations

Giuseppe Daniele, Mariam Alatrach, Christina Agyin, Curtis Triplitt, John M. Adams +9 more

Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin

Diabetes Care(2020)10.2337/dc19-1993
N/A
0.313DataRank · unranked
6 citations

John M. Adams, Carolina Solis‐Herrera, Curtis Triplitt, Ralph A. DeFronzo, Eugênio Cersósimo +1 more

Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies

Diabetes Obesity and Metabolism(2022)10.1111/dom.14767
N/A
0DataRank · unranked
9 citations

Curtiss Puckett, Osama Migahid, Siham Abdelgani, A. Migahed, John M. Adams +5 more

Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients

Diabetes Care(2023)10.2337/dc22-0885
N/A
0DataRank · unranked
26 citations

Ahmed Khattab, John M. Adams, Mohamed Abu‐Farha, Giuseppe Daniele, Fahd Al‐Mulla +4 more

Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes

The Journal of Clinical Endocrinology & Metabolism(2023)10.1210/clinem/dgad438
N/A
0DataRank · unranked
11 citations

Mariam Alatrach, Carolina Solis‐Herrera, Gozde Baskoy, John M. Adams, Andrea Hansis‐Diarte +5 more

Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes

Diabetes Care(2024)10.2337/dc23-1646
N/A
0DataRank · unranked
29 citations

Ahmed Khattab, John M. Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke +4 more

Empagliflozin Reduces Liver Fat in Diabetic and Nondiabetic Subjects

Metabolism(2024)10.1016/j.metabol.2024.155865
N/A
0DataRank · unranked
0 citations

Ahmed Khattab, John M. Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke +4 more

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT

Diabetes Care(2020)10.2337/dc20-0978
N/A
0DataRank · unranked
54 citations

Curtiss Puckett, John M. Adams, Ahmed Khattab, Gozde Baskoy, Eugênio Cersósimo +3 more

Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate: A Randomized Trial

Diabetes(2025)10.2337/db25-0210
N/A
0DataRank · unranked
0 citations

Ahmed A. Khattab, John M. Adams, Fahd Al‐Mulla, Mohamed Abu‐Farha, Gozde Baskoy +6 more

Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes

The Journal of Clinical Endocrinology & Metabolism(2021)10.1210/clinem/dgab403
N/A
0DataRank · unranked
7 citations

Curtiss Puckett, John M. Adams, Curtis Triplitt, Ralph A. DeFronzo, Muhammad Abdul‐Ghani +1 more